Volume 8, Issue 31 (7-2018)                   NCMBJ 2018, 8(31): 9-19 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Amanzadeh A, Molla-kazemiha V, Habibi-Anbouhi M, Azadmanesh K, Mousavi S A, Abolhassani M et al . Induction of programmed cell death by “Retinoic acid, Formylindolo (3, 2-b) carbazole”-enhanced monoclonal antibody against CD44 in acute promyelocytic leukemia cells patients.. NCMBJ. 2018; 8 (31) :9-19
URL: http://ncmbjpiau.ir/article-1-1132-en.html
National Cell Bank of Iran, Pasteur Institute of Iran, Tehran, Iran , shokrgozar1967@gmail.com
Abstract:   (4875 Views)
Aim and Background:
The aim of this study was to enhance the synergistic effect of the "RA-FICZ" by adding anti CD44 monoclonal antibody (mAb), to induce myeloid differentiation and apoptosis in three patients with APL.
Materials and methods:
The anti-CD44 antibody concentrations of 5 to 25 μg/ml prepared and added to "RA-FICZ" complex and Isolated Cells from Patients.The antibody optimum concentration was determined then neutrophil maturation, apoptosis and expression of CD14 and CD11b were analyzed by flow cytometry.
Adding the different concentrations of CD44 mAb against CD44 improved the ability of promyelocytes differentiation and led to increased expression of CD11b and CD14 antigens more than two times. The apoptotic rate increased up to 66%.
Additional studies and work on the animal models can lead to a reduction even elimination of the chemotherapy. This triple combination" can be candidate as a novel differentiation-inducing therapy in APL cells.
Full-Text [PDF 683 kb]   (914 Downloads)    
Type of Study: Research Article | Subject: Cellular and molecular
Received: 2018/09/8 | Accepted: 2018/09/8 | Published: 2018/09/8

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2021 CC BY-NC 4.0 | New Cellular and Molecular Biotechnology Journal

Designed & Developed by : Yektaweb